Phase II trial of pathology-based tripartite treatment stratification for patients with CNS germ cell tumors: A long-term follow-up study
Neuro-Oncology · 07.03.2025 · 27 (3) · 828-840
DOI: 10.1093/neuonc/noae229 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Neuro-Oncology, online erschienen am 02.11.2024. Verfasst von Hirokazu Takami und 39 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Faculty of Medicine, The University of Tokyo Hospital, Tokyo, Japan (H.Takami, S.T., N.Saito). Hauptthemen laut MEDLINE: Neoplasms, Germ Cell and Embryonal, Central Nervous System Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Background
A previous Phase II clinical trial, conducted from 1995 to 2003, evaluated CNS germ cell tumors (GCTs) using a three-group treatment stratification based on histopathology. The primary objective of the study was to assess the long-term efficacy of standardized treatment regimens, while the secondary objective focused on identifying associated long-term complications.
Methods
A total of 228 patients were classified into 3 groups for treatment: germinoma (n = 161), intermediate prognosis (n = 38), and poor prognosis (n = 28), excluding one mature teratoma case. Treatment involved stratified chemotherapy regimens and varied radiation doses/coverage. Clinical data was retrospectively analyzed at a median follow-up of 18.5 years.
Results
The treatment outcomes for germinoma, with or without syncytiotrophoblastic giant cells, were similar. The 10- and 20-year event-free survival rates for the germinoma, intermediate, and poor prognosis groups were 82/76/49% and 73/66/49%, respectively. Overall survival (OS) rates were 97/87/61% at 10 years and 92/70/53% at 20 years. Germinomas in the basal ganglia, treated without whole-brain radiation therapy (WBRT), frequently relapsed but were effectively managed with subsequent WBRT. Deaths in germinoma cases had varied causes, whereas deaths in the poor prognosis group were predominantly disease-related. Nineteen treatment-related complications were identified in 16 patients, with cumulative event rates of 1.9% at 10 years and 11.3% at 20 years. OS rates at 1 and 2 years post-relapse for tumors initially classified as germinoma, intermediate, and poor prognosis were 94/88/18% and 91/50/9%, respectively.
Conclusions
Initial treatment intensity is crucial for managing non-germinomatous GCTs, while long-term follow-up for relapse and complications is imperative in germinomas. Irradiation extending beyond the immediate tumor site is essential for basal ganglia germinomas. Addressing relapse in non-germinomatous GCT remains a significant challenge.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurosurgery, Faculty of Medicine, The University of Tokyo Hospital, Tokyo, Japan (H.Takami, S.T., N.Saito).
- Department of Neuro-Oncology/Neurosurgery, Saitama Medical University International Medical Center, Saitama, Japan (M.M., T.S., R.N.).
- Department of Neurosurgery, Saitama Medical University Hospital, Saitama, Japan (K.T., T.F.).
- Department of Neurosurgery, Hokkaido University School of Medicine, Hokkaido, Japan (M.O., S.Yamaguchi).
- Department of Neurosurgery, Tohoku University Graduate School of Medicine, Miyagi, Japan (M.K.).
- Department of Neurosurgery, Faculty of Medicine, Yamagata University, Yamagata, Japan (K.Matsuda, Y.S.).
ORCID-Profile: Hirokazu Takami, Masayuki Kanamori, Yoshitaka Narita, Yoshiki Arakawa, Fumiyuki Yamasaki, Ryo Nishikawa
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Takami, H., Matsutani, M., Suzuki, T., Takabatake, K., Fujimaki, T., Okamoto, M., Yamaguchi, S., Kanamori, M., Matsuda, K., Sonoda, Y., Natsumeda, M., Ichinose, T., Nakada, M., Muroi, A., Ishikawa, E., Takahashi, M., Narita, Y., Tanaka, S., Saito, N., …, & Nishikawa, R. (2025). Phase II trial of pathology-based tripartite treatment stratification for patients with CNS germ cell tumors: A long-term follow-up study. Neuro-Oncology, 27(3), 828-840. https://doi.org/10.1093/neuonc/noae229
Vancouver
Takami H, Matsutani M, Suzuki T, Takabatake K, Fujimaki T, Okamoto M, et al. Phase II trial of pathology-based tripartite treatment stratification for patients with CNS germ cell tumors: A long-term follow-up study. Neuro-Oncology. 2025;27(3):828-840. doi:10.1093/neuonc/noae229
BibTeX
@article{Takami2025,
author = {Takami, Hirokazu and Matsutani, Masao and Suzuki, Tomonari and Takabatake, Kazuhiko and Fujimaki, Takamitsu and Okamoto, Michinari and Yamaguchi, Shigeru and Kanamori, Masayuki and Matsuda, Kenichiro and Sonoda, Yukihiko and Natsumeda, Manabu and Ichinose, Toshiya and Nakada, Mitsutoshi and Muroi, Ai and Ishikawa, Eiichi and Takahashi, Masamichi and Narita, Yoshitaka and Tanaka, Shota and Saito, Nobuhito and Higuchi, Fumi and Shin, Masahiro and Mineharu, Yohei and Arakawa, Yoshiki and Kagawa, Naoki and Kawabata, Shinji and Wanibuchi, Masahiko and Takayasu, Takeshi and Yamasaki, Fumiyuki and Fujii, Kentaro and Ishida, Joji and Date, Isao and Miyake, Keisuke and Fujioka, Yutaka and Kuga, Daisuke and Yamashita, Shinji and Takeshima, Hideo and Shinojima, Naoki and Mukasa, Akitake and Asai, Akio and Nishikawa, Ryo},
title = {Phase II trial of pathology-based tripartite treatment stratification for patients with CNS germ cell tumors: A long-term follow-up study},
journal = {Neuro-Oncology},
year = {2025},
volume = {27},
number = {3},
pages = {828--840},
doi = {10.1093/neuonc/noae229}
}
EUVIMED